keyword
MENU ▼
Read by QxMD icon Read
search

primary brain tumors

keyword
https://www.readbyqxmd.com/read/29906618/treatment-outcomes-of-17-patients-with-atypical-spinal-meningioma-including-4-with-metastases-a-retrospective-observational-study
#1
Sung Hyun Noh, Kyung Hyun Kim, Dong Ah Shin, Jeong Yoon Park, Seong Yi, Sung Uk Kuh, Keung Nyun Kim, Dong Kyu Chin, Keun Su Kim, Do Heum Yoon, Yong Eun Cho
BACKGROUND CONTEXT: Because of the scarcity of atypical spinal meningioma, there is a lack of research on this type of tumor or its associated metastases. PURPOSE: The aim of this study was to investigate the biological behavior of atypical spinal meningioma and identify its prognostic factors by reviewing surgical and clinical outcomes of patients with these tumors. STUDY DESIGN/SETTING: A retrospective chart review was performed. PATIENT SAMPLE: We retrospectively reviewed the data from all patients who underwent spinal cord tumor excision between 1994 and 2017...
June 12, 2018: Spine Journal: Official Journal of the North American Spine Society
https://www.readbyqxmd.com/read/29905512/cranioplasty-with-a-low-cost-customized-polymethylmethacrylate-implant-using-a-desktop-3d-printer
#2
Jesús A Morales-Gómez, Everardo Garcia-Estrada, Jorge E Leos-Bortoni, Miriam Delgado-Brito, Luis E Flores-Huerta, Adriana A De La Cruz-Arriaga, Luis J Torres-Díaz, Ángel R Martínez-Ponce de León
OBJECTIVE Cranioplasty implants should be widely available, low in cost, and customized or easy to mold during surgery. Although autologous bone remains the first choice for repair, it cannot always be used due to infection, fragmentation, bone resorption, or other causes, which led to use of synthetic alternatives. The most frequently used allogenic material for cranial reconstructions with long-term results is polymethylmethacrylate (PMMA). Three-dimensional printing technology has allowed the production of increasingly popular customized, prefabricated implants...
June 15, 2018: Journal of Neurosurgery
https://www.readbyqxmd.com/read/29905460/identification-of-compounds-that-decrease-glioblastoma-growth-and-glucose-uptake-in-vitro
#3
Catherine J Libby, Sixue Zhang, Gloria A Benavides, Sarah E Scott, Yanjie Li, Matthew Redmann, Anh Nhat Tran, Arphaxad Otamias, Victor Darley-Usmar, Marek Napierala, Jianhua Zhang, Corinne Elizabeth Augelli-Szafran, Wei Zhang, Anita B Hjelmeland
Tumor heterogeneity has hampered the development of novel effective therapeutic options for aggressive cancers, including the deadly primary adult brain tumor glioblastoma (GBM). Intratumoral heterogeneity is partially attributed to the tumor initiating cell (TIC) subset that contains highly tumorigenic, stem-like cells. TICs display metabolic plasticity but can have a reliance on aerobic glycolysis. Elevated expression of GLUT1 and GLUT3 is present in many cancer types, with GLUT3 being preferentially expressed in brain TICs (BTICs) to increase survival in low nutrient tumor microenvironments, leading to tumor maintenance...
June 15, 2018: ACS Chemical Biology
https://www.readbyqxmd.com/read/29904818/pet-imaging-of-68-ga-nodaga-rgd-as-compared-with-18-f-fluorodeoxyglucose-in-experimental-rodent-models-of-engrafted-glioblastoma
#4
Sibel Isal, Julien Pierson, Laetitia Imbert, Alexandra Clement, Charlotte Collet, Sophie Pinel, Nicolas Veran, Aurélie Reinhard, Sylvain Poussier, Guillaume Gauchotte, Steeven Frezier, Gilles Karcher, Pierre-Yves Marie, Fatiha Maskali
BACKGROUND: Tracers triggering αvβ3 integrins, such as certain RGD-containing peptides, were found promising in previous pilot studies characterizing high-grade gliomas. However, only limited comparisons have been performed with current PET tracers. This study aimed at comparing the biodistribution of 18 F-fluorodeoxyglucose (18 F-FDG) with that of 68 Ga-NODAGA-RGD, an easily synthesized monomeric RGD compound with rapid kinetics, in two different rodent models of engrafted human glioblastoma...
June 15, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29901574/paraneoplastic-cerebellar-degeneration-associated-with-cerebellar-hypermetabolism-case-report
#5
Ammar Taha Abdullah Abdulaziz, Xiao Qing Yu, Le Zhang, Xin Yue Jiang, Dong Zhou, Jin Mei Li
RATIONALE: Paraneoplastic cerebellar degeneration (PCD) is an immune-mediated neurological deficit affecting the cerebellum. Anti-Yo antibody positive PCD is a rare occurrence most likely associated with gynecologic or breast malignancies. The identification of the underlying tumor is a diagnostic challenge in many of these patients. PATIENT CONCERNS: We present a 68-year-old woman with acute symptoms of PCD as a first sign of underlying occult malignancy. Further investigation revealed a positive anti-Yo antibody...
June 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29900547/age-and-surgical-outcome-of-low-grade-glioma-in-sweden
#6
A Corell, L Carstam, A Smits, R Henriksson, A S Jakola
BACKGROUND: Low-grade gliomas (LGG) are slow-growing primary brain tumors that typically affect young adults. Advanced age is widely recognized as a poor prognostic factor in LGG. The impact of age on postoperative outcome in this patient group has not been systemically studied. METHODS: We performed a nationwide register-based study with data from the Swedish Brain Tumor Registry (SBTR) for all adults diagnosed with a supratentorial LGG (WHO grade II astrocytoma, oligoastrocytoma, or oligodendroglioma) during 2005-2015...
June 13, 2018: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/29900059/the-possibility-of-cancer-immune-editing-in-gliomas-a-critical-review
#7
REVIEW
Víctor A Arrieta, Bernardo Cacho-Díaz, Junfei Zhao, Raul Rabadan, Li Chen, Adam M Sonabend
The relationship between anti-tumoral immunity and cancer progression is complex. Recently, immune editing has emerged as a model to explain the interplay between the immune system and the selection of genetic alterations in cancer. In this model, the immune system selects cancer cells that grow as these are fit to escape immune surveillance during tumor development. Gliomas and glioblastoma, the most aggressive and most common of all primary malignant brain tumors are genetically heterogeneous, are relatively less antigenic, and are less responsive to immunotherapy than other cancers...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29897572/evaluation-of-complications-and-costs-during-overlapping-transsphenoidal-surgery-in-the-treatment-of-pituitary-adenoma
#8
Michael Karsy, Christian A Bowers, Jonathan Scoville, Bornali Kundu, Mohammed Atef, J Michael Gee, Jian Guan, William T Couldwell
BACKGROUND: Pituitary adenomas are among the most common primary brain tumors. Recently, overlapping surgery has been curbed in many institutions because of the suggestion there might be more significant adverse events, despite several studies showing that complication rates are equivalent. OBJECTIVE: To assess complications and costs associated with overlapping surgery during the transsphenoidal resection of pituitary adenomas. METHODS: A single-center, retrospective cohort study was performed to evaluate the cases of patients who underwent a transsphenoidal approach for pituitary tumor resection...
June 12, 2018: Neurosurgery
https://www.readbyqxmd.com/read/29897522/the-tnf-receptor-family-member-fn14-is-highly-expressed-in-recurrent-glioblastoma-gbm-and-in-gbm-patient-derived-xenografts-with-acquired-temozolomide-resistance
#9
David S Hersh, Bryan G Harder, Alison Roos, Sen Peng, Jonathan E Heath, Teklu Legesse, Anthony J Kim, Graeme F Woodworth, Nhan L Tran, Jeffrey A Winkles
Background: Glioblastoma (GBM) is a difficult-to-treat brain cancer that nearly uniformly recurs, and recurrent tumors are largely therapy-resistant. Our prior work has demonstrated an important role for the TWEAK receptor Fn14 in GBM patho-biology. In this study, we investigated Fn14 expression in recurrent GBM and in the setting of temozolomide (TMZ) resistance. Methods: Fn14 mRNA expression levels in the non-neoplastic brain, primary (newly diagnosed) GBM, and recurrent GBM (post-chemotherapy and radiation) specimens were obtained from the TCGA data portal...
April 20, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29894459/conjunctival-melanoma-metastasis-to-the-contralateral-orbit
#10
Fanglin He, Yuxin Wang, Renbin Jia
BACKGROUND: Malignant melanoma predominantly occurs in whites, and is potentially fatal. Distant metastases often occur in lung, liver, brain, and could occur without prior regional disease. Conjunctival melanoma metastasis to contralateral orbit has never been reported. PATIENT PRESENTATION: A 60-year-old man who underwent a left primary conjunctival neoplasm resection 11 months ago presented for the evaluation of a conjunctival dark-colored mass with a bulging left lower eyelid that directly invaded the orbits bilaterally...
June 11, 2018: Journal of Craniofacial Surgery
https://www.readbyqxmd.com/read/29893791/trastuzumab-versus-observation-for-her2-non-amplified-early-breast-cancer-with-circulating-tumor-cells-eortc-90091-10093-big-1-12-treat-ctc-a-randomized-phase-2-trial
#11
M Ignatiadis, S Litière, F Rothe, S Riethdorf, C Proudhon, T Fehm, K Aalders, H Forstbauer, P Fasching, E Brain, P Vuylsteke, E Guardiola, R Lorenz, K Pantel, K Tryfonidis, W Janni, M Piccart, C Sotiriou, B Rack, J-Y Pierga
Background: Trastuzumab improves the outcome of women with HER2 positive breast cancer. We aimed to assess whether trastuzumab decreases the detection rate of Circulating Tumor Cells (CTCs) in women with high risk, HER2 non-amplified, early breast cancer. Patients and Methods: The EORTC 90091-10093 BIG 1-12 Treat CTC is a phase 2 trial, conducted in 70 hospitals and 6 CTC laboratories across 5 European countries. Patients with centrally confirmed HER2 non-amplified breast cancer and ≥1 centrally confirmed CTC per 15mL of blood by CellSearch® following surgery and (neo)adjuvant chemotherapy were randomized (1:1) to 6 cycles of trastuzumab intravenously versus 18 weeks of observation...
June 11, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29892149/a-preliminary-study-on-the-estimation-of-the-number-of-cancer-patients-eligible-for-hadron-therapy-in-iran-and-fars-province
#12
Mohammad Amin Hosseini, Mohammad Mohamadianpanah, Mohammad Zare-Bandeamiri, Mohammad Amin Mosleh-Shirazi
Hadron therapy (HT) with protons and carbon ions is an advanced radiotherapy technique. As the first report addressing this topic, the present study aimed to estimate the number of patients eligible for HT in Fars province and the whole of Iran. The data were collected through direct inspection of medical records of the patients treated at the Radiotherapy Department, Namazi Hospital, Shiraz, Iran in 2014. The patients who were treated with external-beam radiotherapy and declared to be a resident of Fars province were extracted from the medical records...
May 2018: Iranian Journal of Medical Sciences
https://www.readbyqxmd.com/read/29892069/stat3-labels-a-subpopulation-of-reactive-astrocytes-required-for-brain-metastasis
#13
Neibla Priego, Lucía Zhu, Cátia Monteiro, Manon Mulders, David Wasilewski, Wendy Bindeman, Laura Doglio, Liliana Martínez, Elena Martínez-Saez, Santiago Ramón Y Cajal, Diego Megías, Elena Hernández-Encinas, Carmen Blanco-Aparicio, Lola Martínez, Eduardo Zarzuela, Javier Muñoz, Coral Fustero-Torres, Elena Pineiro, Aurelio Hernández-Laín, Luca Bertero, Valeria Poli, Melchor Sánchez-Martínez, Javier A Menendez, Riccardo Soffietti, Joaquim Bosch-Barrera, Manuel Valiente
The brain microenvironment imposes a particularly intense selective pressure on metastasis-initiating cells, but successful metastases bypass this control through mechanisms that are poorly understood. Reactive astrocytes are key components of this microenvironment that confine brain metastasis without infiltrating the lesion. Here, we describe that brain metastatic cells induce and maintain the co-option of a pro-metastatic program driven by signal transducer and activator of transcription 3 (STAT3) in a subpopulation of reactive astrocytes surrounding metastatic lesions...
June 11, 2018: Nature Medicine
https://www.readbyqxmd.com/read/29891263/treatment-design-and-rationale-for-a-randomized-trial-of-prophylactic-cranial-irradiation-with-or-without-hippocampal-avoidance-for-sclc-premer-trial-on-behalf-of-the-oncologic-group-for-the-study-of-lung-cancer-spanish-radiation-oncology-group-radiation-oncology
#14
Nuria Rodríguez de Dios, Felipe Couñago, José Luis López, Patricia Calvo, Mauricio Murcia, Mikel Rico, Carmen Vallejo, Javier Luna, Itziar Trueba, Cristina Cigarral, Nuria Farre, Rosa Maria Manero, Xavier Durán, Pilar Samper
BACKGROUND: Prophylactic cranial irradiation (PCI) is part of the usual treatment in most patients with small-cell lung cancer (SCLC) and response after treatment of the primary tumor. Clinical evidence suggests that radiation dose received by the hippocampus during whole brain radiotherapy might play a role in radiation-induced neurocognitive decline. PATIENTS AND METHODS: This study is a multicenter phase III trial (NCT02397733) randomizing SCLC patients after informed consent, to receive standard PCI treatment or PCI with hippocampus avoidance (PCI-HA) by using intensity modulated radiation therapy or volumetric modulated arc therapy...
May 10, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29890994/network-based-analysis-of-oligodendrogliomas-predicts-novel-cancer-gene-candidates-within-the-region-of-the-1p-19q-co-deletion
#15
Josef Gladitz, Barbara Klink, Michael Seifert
Oligodendrogliomas are primary human brain tumors with a characteristic 1p/19q co-deletion of important prognostic relevance, but little is known about the pathology of this chromosomal mutation. We developed a network-based approach to identify novel cancer gene candidates in the region of the 1p/19q co-deletion. Gene regulatory networks were learned from gene expression and copy number data of 178 oligodendrogliomas and further used to quantify putative impacts of differentially expressed genes of the 1p/19q region on cancer-relevant pathways...
June 11, 2018: Acta Neuropathologica Communications
https://www.readbyqxmd.com/read/29890725/new-tetrahydroisoquinoline-derivatives-overcome-pgp-activity-in-brain-blood-barrier-and-glioblastoma-multiforme-in-vitro
#16
Iris Chiara Salaroglio, Elena Gazzano, Joanna Kopecka, Konstantin Chegaev, Costanzo Costamagna, Roberta Fruttero, Stefano Guglielmo, Chiara Riganti
P-glycoprotein (Pgp) determines resistance to a broad spectrum of drugs used against glioblastoma multiforme (GB). Indeed, Pgp is highly expressed in GB stem cells and in the brain-blood barrier (BBB), the peculiar endothelium surrounding the brain. Inhibiting Pgp activity in the BBB and GB is still an open challenge. Here, we tested the efficacy of a small library of tetrahydroisoquinoline derivatives with an EC50 for Pgp ≤ 50 nM, in primary human BBB cells and in patient-derived GB samples, from which we isolated differentiated/adherent cells (AC, i...
June 9, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29890518/management-of-primary-tectal-plate-low-grade-glioma-in-pediatric-patients-results-of-the-multicenter-treatment-study-siop-lgg-2004
#17
Ariane Kaufmann, Nicolas U Gerber, Daniela Kandels, Amedeo A Azizi, Rene Schmidt, Monika Warmuth-Metz, Torsten Pietsch, Rolf-Dieter Kortmann, Astrid K Gnekow, Michael A Grotzer
BACKGROUND:  Tectal plate low-grade gliomas (LGGs) most often present with increased intracranial pressure and sometimes as incidental findings from brain imaging. Prognostic factors predicting outcome are largely unknown. METHODS:  From 2004 until 2012, 71 patients with tectal plate LGG from Germany and Switzerland were followed within the SIOP-LGG 2004 study. Median age at diagnosis was 9.7 (range: 0.1-17.5) years, and median follow-up time of surviving patients was 6...
June 11, 2018: Neuropediatrics
https://www.readbyqxmd.com/read/29890272/emerging-strategies-and-future-perspective-in-neuro-oncology-using-transcranial-focused-ultrasound-technology
#18
REVIEW
Giada Toccaceli, Roberto Delfini, Claudio Colonnese, Antonino Raco, Simone Peschillo
Despite the progress achieved in recent years, the prognosis of patients with primary brain tumors remains poor. Research efforts have therefore focused on identifying more effective and minimally invasive treatment methods. MR guided transcranial focused ultrasound (MRgFUS) is a consolidated minimally invasive therapeutic technique, which has recently acquired a role also in the treatment of some non-oncological intracranial pathologies. In this article, we've reviewed the latest studies to take stock of the potential that this method can offer...
June 8, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29887919/megf10-a-glioma-survival-associated-molecular-signature-predicts-idh-mutation-status
#19
Guanzhang Li, Zhiliang Wang, Chuanbao Zhang, Xing Liu, Fuqiang Yang, Lihua Sun, Jingshan Liang, Huimin Hu, Yanwei Liu, Gan You, Zhaoshi Bao, Wei Zhang, Zheng Wang, Tao Jiang
Glioma is the most common primary brain tumor with various genetic alterations; among which, IDH mutation is the most common mutation and plays an important role in glioma early development, especially in lower grade glioma (LGG, WHO II-III). Previous studies have found that IDH mutation is tightly associated with extensive methylation across whole genome in glioma. To further investigate the role of IDH, we obtained methylation data of 777 samples from CGGA (Chinese Glioma Genome Atlas) and TCGA (The Cancer Genome Atlas) with IDH mutation status available...
2018: Disease Markers
https://www.readbyqxmd.com/read/29886836/a-multi-targeted-natural-flavonoid-myricetin-impedes-abnormal-glioblastoma-cell-motility-and-invasiveness-via-suppressing-lamellipodia-and-focal-adhesions-formation
#20
Hua-Fu Zhao, Gang Wang, Chang-Peng Wu, Xiu-Ming Zhou, Jing Wang, Zhong-Ping Chen, Shing-Shun Tony To, Wei-Ping Li
BACKGROUND: Glioblastoma multiforme (GBM) is the most aggressive and malignant primary brain tumor characterized by rapid growth and extensive infiltration to neighboring normal brain parenchyma, which contribute to tumor recurrence and poor prognosis. Myricetin is a natural flavonoid with potent anti-oxidant, anti-inflammatory and anti-cancer activities, which may serve as a potential and harmless agent for GBM treatment. METHODS: To investigate the anti-glioblastoma effects of myricetin, GBM cells were treated with myricetin alone or in combination with temozolomide...
June 10, 2018: CNS & Neurological Disorders Drug Targets
keyword
keyword
34822
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"